Patents by Inventor Louis J. Theodore
Louis J. Theodore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7115248Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: GrantFiled: April 8, 2004Date of Patent: October 3, 2006Assignee: NeoRx CorporationInventors: Sudhakar Kasina, John M Reno, Louis J Theodore
-
Patent number: 7078013Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: GrantFiled: February 10, 2004Date of Patent: July 18, 2006Assignee: Aletheon Pharmaceuticals, Inc.Inventors: Donald B Axworthy, Louis J Theodore, Linda M Gustavson, John M Reno
-
Patent number: 6908903Abstract: Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.Type: GrantFiled: October 12, 2000Date of Patent: June 21, 2005Assignee: Aletheon Pharmaceuticals, Inc.Inventors: Louis J. Theodore, Donald B. Axworthy
-
Publication number: 20040241172Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: ApplicationFiled: February 10, 2004Publication date: December 2, 2004Applicant: NeoRx CorporationInventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Alan R. Fritzberg
-
Patent number: 6709652Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: GrantFiled: August 1, 2001Date of Patent: March 23, 2004Assignee: NeoRx CorporationInventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
-
Publication number: 20030220233Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: ApplicationFiled: June 6, 2003Publication date: November 27, 2003Applicant: NeoRx CorporationInventors: Sudhakar Kasina, John M. Reno, Louis J. Theodore
-
Publication number: 20030129191Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Clearing agents and clearance mechanisms are also discussed.Type: ApplicationFiled: April 17, 2002Publication date: July 10, 2003Applicant: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno
-
Publication number: 20030099640Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.Type: ApplicationFiled: February 12, 2002Publication date: May 29, 2003Applicant: NeoRx CorporationInventors: Louis J. Theodore, John M. Reno, Linda M. Gustavson
-
Patent number: 6416738Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Clearing agents and clearance mechanisms are also discussed.Type: GrantFiled: April 25, 2000Date of Patent: July 9, 2002Assignee: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno
-
Publication number: 20020034511Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: ApplicationFiled: August 1, 2001Publication date: March 21, 2002Inventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
-
Patent number: 6358490Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.Type: GrantFiled: May 21, 1999Date of Patent: March 19, 2002Assignee: NeoRx CorporationInventors: Louis J. Theodore, John M. Reno, Linda M. Gustavson
-
Publication number: 20020015705Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.Type: ApplicationFiled: May 21, 1999Publication date: February 7, 2002Inventors: LOUIS J. THEODORE, JOHN M. RENO, LINDA M. GUSTAVSON
-
Patent number: 6287536Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: GrantFiled: January 27, 1997Date of Patent: September 11, 2001Assignee: NeoRx CorporationInventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
-
Patent number: 6172045Abstract: Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.Type: GrantFiled: June 6, 1996Date of Patent: January 9, 2001Assignee: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy
-
Patent number: 6075010Abstract: Small molecule weight clearing agents containing ligands such as biotin or biotin analogs and hexose residue, in particular galactose or N-acetyl galactosamine residues are taught. These clearing agents effectively clear anti-ligand containing conjugates in vivo via hepatocyte receptor mediated clearance mechanisms.Type: GrantFiled: December 7, 1994Date of Patent: June 13, 2000Assignee: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno
-
Patent number: 6022966Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.Type: GrantFiled: November 22, 1993Date of Patent: February 8, 2000Assignee: NeoRx CorporationInventors: Linda M. Gustavson, Louis J. Theodore, Fu-Min Su, John M. Reno
-
Patent number: 6015897Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-N-methylglycyl-seryl-O-succinamido-benzyl DOTA is disclosed.Type: GrantFiled: May 13, 1996Date of Patent: January 18, 2000Assignee: NeoRx CorporationInventors: Louis J. Theodore, Sudhakar Kasina, John M. Reno, Linda M. Gustavson
-
Patent number: 5985826Abstract: Hepatic-directed compounds, reagents useful in making such compounds and associated methods and compositions are disclosed. Hepatic-directed compounds are processed by metabolic mechanisms, which generally differ in degree or in kind from the metabolic mechanisms encountered by compounds which are not so directed. Hepatic-directed compounds useful in the methods disclosed include a hexose cluster characterized by multiple hexose residues connected in an iteratively branched configuration. In one embodiment, the hexose cluster comprises at least four hexose residues with each branch of the configuration having two prongs. In another embodiment, the hexose cluster comprises at least nine hexose residues with each branch of the configuration having three prongs.Type: GrantFiled: March 3, 1997Date of Patent: November 16, 1999Assignee: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno
-
Patent number: 5955605Abstract: Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.Type: GrantFiled: August 12, 1996Date of Patent: September 21, 1999Assignee: NeoRx CorporationInventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno
-
Patent number: 5886143Abstract: Hepatic-directed compounds, reagents useful in making such compounds and associated methods and compositions are discussed. Hepatic-directed compounds are processed by metabolic mechanisms, which generally differ in degree or in kind from the metabolic mechanisms encountered by compounds which are not so directed. Reagents useful in the preparation of hepatic-directed compounds include a hexose cluster characterized by multiple hexose residues connected in an iteratively branched configuration. In one embodiment, the hexose cluster comprises at least four hexose residues with each branch of the configuration having two prongs. In another embodiment, the hexose cluster comprises at least nine hexose residues with each branch of the configuration having three prongs.Type: GrantFiled: December 7, 1994Date of Patent: March 23, 1999Assignee: NeoRx CorporationInventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno